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ORIGINAL ARTICLE
Spectrum of interstitial lung disease from a tertiary care hospital in Karachi
Ali Bin Sarwar Zubairi, Maryam Hassan, Talha Shahzad, Sajjad Sarwar, Aamir Abbas, Huzaifa Ahmad, Muhammad Irfan

Abstract
Objective: To determine the clinical features and patterns of interstitial lung disease.
Methods: This retrospective study was conducted at the Aga Khan University Hospital, Karachi, and comprised
record of patients diagnosed with interstitial lung disease from January 2005 to December 2015. All patients aged
16 years and above diagnosed with interstitial lung disease on the basis of clinical features, radiological features on
high-resolution computed tomography of the chest, and lung biopsies were included. SPSS 19 was used for data
analysis.
Results: Of the 537 patients, 324(60.3%) of the participants were females. The overall mean age was 60.5±14.9 years.
The most common co-morbid condition was diabetes mellitus in 72(13.4%) patients, followed by hypertension in
48(8.9%) and ischaemic heart disease in 21(3.9%). The most common interstitial lung disease was idiopathic
pulmonary fibrosis in 217(40.4%) patients, followed by non-specific interstitial pneumonia in 106(19.7%), sarcoidosis
in 82(15.3%) and connective tissue disease-related interstitial lung disease in 56(10.4%) patients.
Conclusion: Idiopathic pulmonary fibrosis was found to be the most common interstitial lung disease subtype
followed by non-specific interstitial pneumonia, sarcoidosis and connective tissue disease-related-interstitial lung
disease.
Keywords: Interstitial lung disease, Idiopathic pulmonary fibrosis, Pakistan. (JPMA 67: 1065; 2017)

Introduction
Interstitial lung disease (ILD) or diffuse parenchymal
lung disease comprises a diverse group of more than
200 conditions that damage the lung parenchyma.
These entities manifest in varying degrees of
inflammation and fibrosis that result in characteristic
clinical,
radiological,
and
histopathological
presentations. Two-thirds of ILD cases are idiopathic.
The remainder are associated with drugs,
environmental exposure, autoimmunity, infections or
genetics.1,2 The diagnosis of ILD can be challenging and
requires a multidisciplinary approach involving
evaluation by a pulmonologist, radiologist and
histopathologist with expertise in ILD.
Epidemiological data on ILD from around the world is
limited. Recently efforts have been made to establish ILD
registries in several countries, to gain a better
understanding of the disease. In 2013 the British Thoracic
Society established an ILD registry that aimed to study
clinical and diagnostic trends of idiopathic pulmonary
fibrosis (IPF) and sarcoidosis in Britain.3 Similarly in
Germany, Exploring Clinical and Epidemiological
Characteristics of Interstitial Lung Diseases (EXCITING-ILD)
was established to determine the spectrum of ILD in the
country.4 The registries of ILD from other European
Aga Khan University, Karachi.
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countries like Belgium and Spain shows differences in
incidences of various forms of ILDs as well.5-7 A singlecentre study in Romania showed IPF to be the more
predominant ILD, followed by hypersensitivity
pneumonia.8
In Asia, a few registries have published their results.
Recent data published by the ILD Pakistan registry,
which collected data from 2010-2016, showed IPF to be
the most common ILD (32.9%), followed by sarcoidosis
(18.5%).9 In India, a prospective ILD registry found
hypersensitivity pneumonitis as the most common ILD
(47.35%).10
There is a lack of data on ILD from developing countries.
The diagnosis of this condition in Pakistan is even more
challenging due to higher prevalence of tuberculosis
leading to fibrosis which can mimic ILD. Limited resources
and poor socio-economic conditions also hinder the
timely diagnosis of the disease.
The current study was planned to analyse the spectrum of
ILD. This data is expected to help us understand the
various spectra of this disease in our population and
provide opportunities for further studies.

Patients and Methods
This retrospective, observational study was conducted at
the Aga Khan University Hospital (AKUH), Karachi, and
comprised records of patients diagnosed with ILD from
January 2005 till December 2015. The AKUH is a tertiary
J Pak Med Assoc
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care hospital with a total of 640 beds.All adult patients
with suspected ILD on the basis of clinical history and
radiological features on high-resolution computed
tomography (HRCT) scan of the chest were reviewed by a
multidisciplinary team consisting of a senior
pulmonologist and radiologist with expertise in diagnosis
of ILD. The files were retrieved using International
Classification of Diseases-9 (ICD-9) coding. The definite
diagnosis of ILD was based on histopathology if available.
Other cases were labelled as ILD on the basis of clinical
and HRCT findings. Patients with post-infectious fibrosis
or bronchiectasis were excluded (Figure).
The study was reviewed and approved by the institutional
ethical review committee. The data was collected through
medical records. The information about demographic
variables, occupation, environmental exposures, smoking,
medications, co-morbid conditions, radiological and
pathological pattern, severity and treatment of the
disease were collected in a predesigned questionnaire.
The American Thoracic Society/European Respiratory
Society Statement on Update of the International
Multidisciplinary Classification of the Idiopathic Interstitial
Pneumonias 2013 was used in the diagnosis and
classification of ILD.11 Interstitial lung diseases were
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classified into different categories including IPF, nonspecific interstitial pneumonitis (NSIP), hypersensitivity
pneumonitis (HP), cryptogenic organising pneumonia
(COP), sarcoidosis, connective tissue disease-associated
interstitial lung disease (CTD-ILD) and other rare
interstitial lung diseases depending upon the patient's
clinical presentation, laboratory investigations, lung
function tests, environmental exposures, radiological
findings and pathological diagnosis if available.
The following HRCT descriptive findings were used to
classify ILDs:
IPF: The presence of bilateral honeycombing, reticular
opacities, traction bronchiectasis, sub pleural cysts with
minimal or no ground glass opacities and predominant
basal involvementwith exclusion of other causes of ILD.11
NSIP: The presence of ground glass opacities, irregular
linear or reticular infiltrates and associated with traction
bronchiectasis with most commonly bilateral and
symmetrical distribution.
HP: poorly defined centrilobularmicronodules, widespread
ground-glass opacities, mosaic attenuation and air
trapping with a predominance of disease in upper and
middle lung zones under appropriate clinical setting.12
COP: Presence of multiple
patchy alveolar opacities with a
peripheral
and
bilateral
distribution, ground glass
opacities and peribronchiolar
nodules extending into the lung
parenchyma.11
Sarcoidosis: The presence of
mediastinal lymphadenopathy,
nodular
opacities
and
micronodules
along
bronchovascular
bundles,
central
bronchovascular
thickening and nodularity,
confluent nodular opacities with
air bronchograms, ground glass
opacities, crowding and central
retraction of bronchi and vessels
near the hilae, and pleural or
subpleural nodules.13

TB: Tuberculosis.

Figure: Flow Chart of the Study.
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Pulmonary langerhans cell
histiocytosis (PLCH): the
combination of multiple cysts
and nodules, with mid to upper
zone
predominance,
and
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interstitial thickening.14

Table-2: Characteristics of patients with common ILDs.

Pulmonary lymphangioleiomyomatosis (LAM): the
presence of numerous thin-walled cysts, ranging in size
from a few millimetres to six centimetres, scattered
throughout both lungs with normal intervening lung
parenchyma.15
Pulmonary alveolar proteinosis (PAP): the presence of
ground glass and/or consolidative infiltrates in patchy or
diffuse distributions, reticular opacities or interlobular
septal thickening present within the airspace infiltrates,
creating a "crazy-paving" pattern on HRCT.16
CTD-ILD: The ILD pattern on HRCT along with the clinical
and serologic evidence of connective tissue disease.
The data was analysed using the SPSS 19. Means and
standard deviations were reported for quantitative
variables and frequencies with percentages were
reported for qualitative variables. Variables such as
gender, age, smoking status, clinical presentation and
pulmonary function tests (PFT) were analysed to
determine their distribution across ILD subtypes.
Independent sample t-test was used to compare the
mean age of IPF and non-IPF ILD. Depending on the
minimum expected cell count, chi-square or Fisher's exact
test was used to check the association between types of
ILD and different qualitative variables. Logistic regression
was used to calculate crude and adjusted odds ratio for
the factors associated with IPF versus non-IPF ILDs.

Results
Of the 791 files reviewed, 537(67.8%) met the inclusion
criteria. The overall mean age was 60.5±14.9 years and
Table-1: Distribution of ILD subtypes.
Clinical Types
Idiopathic Pulmonary Fibrosis (IPF)
Non Specific Interstitial Pneumonia (NSIP)
Connective Tissue Disease ILD (CTD-ILD)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Systemic Sclerosis (SS)
Mixed Connective Tissue Disease (MCTD)
Sarcoidosis
Hypersensitivity Pneumonitis (HP)
Cryptogenic organizing pneumonia (COP)
Desquamative Interstitial Pneumonia (DIP)
Pulmonary Langerhans Cell Histiocytosis (PLCH)
Drug Induced
Protein Alveolar Proteinosis (PAP)
Lymphangioleiomyomatosis (LAM)
Autoimmune-associated ILD
ILD: Interstitial lung disease.

N (%)
217 (40.4)
106 (19.7)
56 (10.4)
30 (53.5)
8 (14.2)
11 (19.6)
7 (12.5)
82 (15.3)
30 (5.6)
15 (2.8)
11 (2.0)
3 (0.6)
6 (1.1)
3 (0.6)
3 (0.6)
2 (0.4)

IPF
n=217
Mean Age
67.2±12.1
Male/Female
112/105
Smoking Status n(%)
Current Smoker
50(23.04)
Ex-smoker
53(24.4)
Never Smoked
114(52.5)
Symptoms n(%)
Cough
193(88.9)
Dyspnoea
205(94.4)
Clubbing
32(14.7)
Crackles
205(94.4)
Clinical Onset n(%)
Acute
4(1.8)
Sub-acute
5(2.3)
Chronic
208(95.8)
PFT (n=195) n(%)
Non Specific
89 (93.7)
Obstructive
0 (0.0)
Mixed
3 (3.2)
Normal
3 (3.2)

NSIP
n=106

Sarcoidosis
n=82

CTD-ILD
n=56

58.4±15.6
28/78

55.5±11.6
34/48

54.1±15.6
7/49

9(8.4)
16(15.09)
81(76.4)

1(1.2)
10(12.19)
71(86.5)

3 (5.3)
6(10.7)
45(80.3)

97(91.5)
102(96.2)
9(8.4)
91(85.8)

76(92.6)
70(85.3)
2(2.4)
53(64.6

52(92.8)
54(96.4)
7(12.5)
51(91.07)

1(0.9)
6(5.6)
99(93.3)

5(6.09)
6(7.3)
71(86.5)

1(1.7)
3(5.3)
52(9.2)

32 (82.1)
5 (12.8)
2 (5.1)
0 (0.0)

28 (70.0)
6 (15.0)
4 (10.0)
2 (5.0)

16 (76.2)
2 (9.5)
3 (14.3)
0 (0.0)

ILD: Interstitial lung disease
IPF: Idiopathic pulmonary fibrosis
NSIP: Non-specific interstitial pneumonitis (
CTD-ILD: Connective tissue disease-associated interstitial lung disease
SD: Standard deviation
PFT: Pulmonary function test.

324(60.3%) of the participants were females. Diabetes
mellitus was found to be the most common co-morbid
condition, seen in 72(13.4%) patients, followed by
hypertension in 48(8.9%) patients and ischaemic heart
disease in 21(3.9%) patients (Table-1).
IPF was the most common ILD which occurred in
217(40.4%) individuals, followed by NSIP in 106(19.6%)
patients, sarcoidosis in 82(15.3%) and CTD-ILD in
56(10.4%) patients (Table-2).
All of the ILD types were found to be more predominant
in the female population except IPF. The mean age was
different across the various types of ILD (p<0.01); patients
with NSIP, CTD-ILD and sarcoidosis presented at a
younger age in contrast to IPF.
As IPF was the most common pattern in our study, we also
compared the characteristics of IPF with other types of
ILD (Table-3).
On logistic regression analysis, age greater than 60 years
(odds ratio [OR] 3.4; 95% confidence interval [CI] 2.3 to 5.0)
and male gender (OR 2.1; 95% CI 1.4 to 3.2) were
significantly associated with IPF as compared to non-IPF
J Pak Med Assoc
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Table-3: Comparison of Characteristics of IPF and other ILDs.

Age Mean
Gender n (%)
Male
Female
Smoking n (%)
Non-smoker
Smoker
Cough n (%)
Yes
No
Dyspnoea n (%)
Yes
No
Crackles n (%)
Yes
No
Clubbing n (%)
Yes
No
Onset n (%)
Acute
Subacute
Chronic
PFTs n (%)
Non-specific
Obstructive
Mixed
Normal

IPF

Others

p value

67.24±12.13

55.97±14.95

<0.01

112 (51.6)
105 (48.4)

101 (31.6)
219 (68.4)

<0.01

167 (77)
50 (23)

290 (90.6)
30 (9.4)

<0.01

194 (89.4)
23 (10.6)

296 (92.5)
24 (7.5)

0.21

205 (94.5)
12 (5.5)

302 (94.4)
18 (5.6)

0.96

205 (94.5)
12 (5.5)

265 (82.8)
55 (17.2)

<0.01

32 (14.7)
185 (85.3)

22 (6.9)
298 (93.1)

<0.01

4 (1.8)
5 (2.3)
208 (95.9)

15 (4.7)
23 (7.2)
282 (88.1)

0.01

89 (93.7)
0 (0)
3 (3.2)
3 (3.2)

101 (78.9)
15 (11.7)
10 (7.8)
2 (1.6)

<0.01

IPF: Idiopathic pulmonary fibrosis. ILD:Interstitial lung disease. PFT:Pulmonary function test.
SD: Standard deviation.

Table-4: Logistic regression model showing factors associated with IPF versus non-IPF ILDs.
Variable

Univariate
Unadjusted OR
95% CI

Age
>60
< 60
Gender
Male
Female
Crackles
Yes
No
Clubbing
Yes
No
Smoking
Current Smoker
Non Smoker
Clinical Onset
Chronic
Sub-acute
Acute

3.6
1

2.5 to 5.3

3.4
1

2.3 to 5.0

2.3
1

1.6 to 3.3

2.1
1

1.4 to 3.2

3.6
1

1.9 to 6.8

2.8
1

1.4 to 5.6

2.3
1

1.3 to 4.2

2.6
1

1.3 to 5.0

2.9
1

1.8 to 4.7

1.4
1

0.8 to 2.5

2.8
0.8
1

0.9 to 8.5
0.2 to 3.5

2.2
0.7
1

0.7 to 7.0
0.1 to 3.0

IPF: Idiopathic pulmonary fibrosis
ILD: Interstitial lung disease.
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Multivariate
Adjusted OR
95% CI

ILDs when adjusted for smoking status and clinical onset
of disease (Table-4).

Discussion
We identified IPF, NSIP, sarcoidosis and CTD-ILD as the four
most common ILD subtypes in our population. Our data is
consistent with findings reported from the ILD Pakistan
(ILDPAK) registry and from Greece.17 ILD was more
common in females in our study population. This finding
is in accordance with the results of the ILDPAK and Indian
registry, while in contrast to those from New Mexico and
Belgium which found that ILD is more common among
males due to occupational exposure.6,18 The majority of
females in our study were housewives.
In our study population, IPF was found to be the most
common type of ILD. The higher prevalence of IPF (40.4%)
in our region is important to note when compared with
data from Greece (20.1%) and Saudi Arabia (23.3%).13,19
However, our data differs from the results of the
prospective ILD registry in India in which hypersensitivity
pneumonitis was found to be the most common ILD
(47.35%).10 Data from a single-centre study from India
showed similar findings with IPF present in 45% patients
in the study.20 The results of logistic regression analysis
showed that age more than 60 was significantly
associated with IPF in our population. Previous studies
have suggested that aging increases susceptibility to
developing IPF, however, the link between the two
remains unclear.21
Sarcoidosis was the third most prevalent type of ILD in our
study. In contrast, sarcoidosis was found to be the
predominant ILD in studies from Greece, Belgium and
Spain.17,22 These differences can be attributed to racial
and regional differences. The incidence of sarcoidosis in
the Pakistani population is underestimated, as the disease
is commonly undiagnosed because it can be
asymptomatic and patients are often mistreated as
having tuberculosis.
CTD-ILD was the fourth-most common ILD among our
patient population. Among the CTD-ILD, rheumatoid
arthritis (RA) was found to be the most common subtype
in our female population. The mean age of the patients
presenting with CTD-ILD (54.1 years) was less than the
other ILDs. This earlier presentation might be due to the
nature of the disease, which commonly occurs in younger
patients.
The current study was one of the largest studies on
spectrum of ILD from Pakistan.
It is unclear what the true burden of the disease is in the
region. ILD is often unrecognised and unreported due to
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a lack of knowledge about the diagnostic criteria and
resources available to recognise the disease pattern.

7.

The current study had its limitations as well. As a singlecentre study, our data was not generalisable. The risk
factors for ILD were difficult to assess from the
retrospective data. In Pakistan, where most of the
healthcare expenditure is paid out of pocket, cost is a
major obstacle for evaluation of ILD. Pulmonary function
tests were not performed in a majority of patients due to
cost implications. Inability to perform histopathology for
definitive diagnosis was another limitation of our study.

8.

9.

10.

11.

Conclusion
IPF was found to be the most common ILD, followed by
NSIP, sarcoidosis and CTD-ILD. Larger multi-centre studies
are required nationwide to establish the true prevalence
of ILD in Pakistan.

12.

Disclaimer: None.

13.

Competing Interests: None.

14.

Source of Funding: None.
15.

References
1.

2.
3.

4.

5.

6.

Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P,
Beiderbeck A, et al. The incidence of interstitial lung disease 19952005: a Danish nationwide population-based study. BMC Pulm
Med 2008;8:24.
King TE, Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis.
Lancet (London, Engl). 2011;378(9807):1949-61.
British Thoracic Society Interstitial Lung Disease Registry
Programme Annual Report 2015-2016 (online) (cited 2017 Jan 9)
Available from URL: https://www.brit-thoracic.org.uk/documentlibrar y/audit-and- qualit y-improvement/lung- disease registry/bts-ild-registry-annual-report-201516.
Kreuter M, Herth FJ, Wacker M, Leidl R, Hellmann A, Pfeifer M, et al.
Exploring Clinical and Epidemiological Characteristics of
Interstitial Lung Diseases: Rationale, Aims, and Design of a
Nationwide Prospective Registry--The EXCITING-ILD Registry.
BioMed Res Int;2015:123876.
Demedts M, Wells AU, Anto JM, Costabel U, Hubbard R, Cullinan P,
et al. Interstitial lung diseases: an epidemiological overview. Eur
Resp J Suppl; 2001; 32:2s-16s.
Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M.
Comparison of registries of interstitial lung diseases in three
European countries. Eur Resp J Suppl; 2001; 32:114s-8s.

16.

17.

18.

19.
20.

21.

22.

Lopez-Campos JL, Rodriguez-Becerra E. Incidence of interstitial
lung diseases in the south of Spain 1998-2000: the RENIA study.
Eur J Epidemiol 2004;19:155-61.
Strambu I, Belaconi I, Stoicescu I, Ionita D, Cojocaru F, Nita C, et al.
Interstitial lung diseases: an observational study in patients
admitted in "Marius Nasta" Institute of Pulmonology Bucharest,
Romania, in 2011. Pneumologia (Bucharest, Romania).
2013;62:206-11.
Ansarie M. A national guideline and ILD PAK Registry Report:
Recent landmarks in the understanding of interstitial lung
diseases in Pakistan. J Pak Med Assoc. 2016;66:1050-3.
Singh S, Collins BF, Sharma BB, Joshi JM, Stalwart D, Katiyar S, et al.
Interstitial Lung Disease (ILD) in India: Results of a Prospective
Registry. Am J Resp Crit care med 2017;195:801-13.
Travis WD, Costabel U, Hansell DM, King TE, Jr., Lynch DA,
Nicholson AG, et al. An official American Thoracic
Society/European Respiratory Society statement: Update of the
international multidisciplinary classification of the idiopathic
interstitial pneumonias. Am J Resp Crit care med 2013;188:733-48.
Glazer CS, Rose CS, Lynch DA. Clinical and radiologic
manifestations of hypersensitivity pneumonitis.J Thorac Imag.
2002;17:261-72.
Lynch JP, 3rd. Computed tomographic scanning in sarcoidosis.
Semin Resp Crit Care Med. 2003;24:393-418.
Brauner MW, Grenier P, Tijani K, Battesti JP, Valeyre D. Pulmonary
Langerhans cell histiocytosis: evolution of lesions on CT scans.
Radiology. 1997;204:497-502.
Johnson S. Rare diseases. Lymphangioleiomyomatosis: clinical
features, management and basic mechanisms. Thorax.
1999;54:254-64.
Frazier AA, Franks TJ, Cooke EO, Mohammed TL, Pugatch RD,
Galvin JR. From the archives of the AFIP: pulmonary alveolar
proteinosis. Radiographics 2008;28:883-99; quiz 915.
Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M,
Markopoulou A, et al. Epidemiology of interstitial lung diseases in
Greece. Respiratory Medicine. 2009;103:1122-9.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology
of interstitial lung diseases.American journal of respiratory and
critical care medicine. 1994;150:967-72.
Alhamad EH. Interstitial lung diseases in Saudi Arabia: A singlecenter study. Ann Thorac Med. 2013;8:33-7.
Subhash HS, Ashwin I, Solomon SK, David T, Cherian AM, Thomas
K. A comparative study on idiopathic pulmonary fibrosis and
secondary diffuse parenchymal lung disease.Indian J Med Sci.
2004;58:185-90.
Selman M, Rojas M, Mora AL, Pardo A. Aging and interstitial lung
diseases: unraveling an old forgotten player in the pathogenesis
of lung fibrosis. Semin Resp Crit Care Med. 2010;31:607-17.
Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory
health and disease in Europe: the new European Lung White Book.
Eur Resp J. 2013;42:559-63.

J Pak Med Assoc

